Hyperkalemia with Mineralocorticoid Receptor Antagonist Use in People with CKD: Understanding and Mitigating the Risks

Overview

Journal Clin J Am Soc Nephrol

Specialty Nephrology

Date 2021 Dec 2

PMID 34853060

Citations 5

Authors

Murray Epstein

Roberto Pecoits-Filho

Catherine M Clase

Manish M Sood

Csaba P Kovesdy

Affiliations

Soon will be listed here.

Citing Articles

Drug Development in Pediatric Chronic Kidney Disease: A Review of Promising Treatments, Old Challenges, and New Strategies.

Kula A Paediatr Drugs. 2025; .

PMID: 39928268 DOI: 10.1007/s40272-025-00684-8.

Cardiovascular Efficacy and Safety of Finerenone: A Meta-Analysis of Randomized Controlled Trials.

Ahmed M, Ahsan A, Shafiq A, Maniya M, Jain H, Iqbal J Clin Cardiol. 2025; 48(2):e70065.

PMID: 39911073 PMC: 11799767. DOI: 10.1002/clc.70065.

Hyperkalemia Incidence in Patients With Non-Dialysis Chronic Kidney Disease: A Large Retrospective Cohort Study From United States Clinical Care.

van Boemmel-Wegmann S, Bauer C, Schuchhardt J, Hartenstein A, James G, Pessina E Kidney Med. 2024; 6(10):100879.

PMID: 39328959 PMC: 11424931. DOI: 10.1016/j.xkme.2024.100879.

Long-term Patiromer Use and Outcomes Among US Veterans With Hyperkalemia and CKD: A Propensity-Matched Cohort Study.

Obi Y, Thomas F, Dashputre A, Goedecke P, Kovesdy C Kidney Med. 2024; 6(1):100757.

PMID: 38192434 PMC: 10772292. DOI: 10.1016/j.xkme.2023.100757.

Kreiner F, Schytz P, Heerspink H, von Scholten B, Idorn T Biomedicines. 2023; 11(9).

PMID: 37760939 PMC: 10526045. DOI: 10.3390/biomedicines11092498.

References

Juurlink D, Mamdani M, Lee D, Kopp A, Austin P, Laupacis A . Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med. 2004; 351(6):543-51. DOI: 10.1056/NEJMoa040135. View

Clase C, Carrero J, Ellison D, Grams M, Hemmelgarn B, Jardine M . Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2019; 97(1):42-61. DOI: 10.1016/j.kint.2019.09.018. View

Pitt B, Kober L, Ponikowski P, Gheorghiade M, Filippatos G, Krum H . Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur Heart J. 2013; 34(31):2453-63. PMC: 3743070. DOI: 10.1093/eurheartj/eht187. View

Epstein M . Hyperkalemia constitutes a constraint for implementing renin-angiotensin-aldosterone inhibition: the widening gap between mandated treatment guidelines and the real-world clinical arena. Kidney Int Suppl (2011). 2019; 6(1):20-28. PMC: 6340904. DOI: 10.1016/j.kisu.2016.01.004. View

Bakris G, Agarwal R, Anker S, Pitt B, Ruilope L, Rossing P . Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med. 2020; 383(23):2219-2229. DOI: 10.1056/NEJMoa2025845. View